Q-omics provides the consensus-scored SUN5 profile across patient tissues and cancer cell-line models. SUN5 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SUN5 is differentially expressed in 2, with the highest sampling consensus in PRAD. Additionally, SUN5 RNA expression shows 6,449 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, PRAD, and STAD as cancer lineages where SUN5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUN5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUN5 survival associations across molecular data types. SUN5 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUN5 RNA expression–survival associations across cancer types. High SUN5 expression shows unfavorable associations in KIRC, ACC, MESO and COAD, but favorable associations in ESCA and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SUN5 RNA expression.
This table summarizes SUN5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SUN5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUN5 shows higher tumor expression in PRAD and KIRC. The PRAD box plot shows higher SUN5 RNA expression in tumor versus normal tissue (log2 FC = +0.013, t-test p = .036).
This table shows molecular features associated with SUN5 in patient tissues and cancer cell lines. In patient samples, SUN5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SUN5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and STOMACH.
